AE37 Peptide vaccine + Pembrolizumab
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple-negative Breast Cancer
Conditions
Triple-negative Breast Cancer
Trial Timeline
May 3, 2019 → Jun 30, 2024
NCT ID
NCT04024800About AE37 Peptide vaccine + Pembrolizumab
AE37 Peptide vaccine + Pembrolizumab is a phase 2 stage product being developed by Merck for Triple-negative Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04024800. Target conditions include Triple-negative Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04024800 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Triple-negative Breast Cancer